Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Unraveling the oligometastatic phenotype and its association with pancreatic cancer survival.
Authors
John D Karalis
University of Texas Southwestern Medical Center, Dallas, TX
John D Karalis , Ahmed Elamir , Gilbert Zvikomborero Murimwa , Sebastian Enrico , Kishore Balasubramanian , Megan Wachsmann , Zhikai Chi , Todd Anthony Aguilera , Patricio Polanco , Matteo Ligorio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Other
DOI
10.1200/JCO.2022.40.4_suppl.618
Abstract #
618
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Early tumor shrinkage as a predictor of survival in patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407.
First Author: Shun Tezuka
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
First Author: Marytere Herrera
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Associations between BMI, morphomics and survival in 528 patients with metastatic pancreatic cancer.
First Author: Valerie Gunchick
Poster
2023 ASCO Annual Meeting
A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.
First Author: Richard Tuli